{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:03:46Z","timestamp":1793930626305,"version":"4.8.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pancretan Health Association"},{"name":"Research Account of the University of Crete","award":["KA10210"],"award-info":[{"award-number":["KA10210"]}],"id":[{"id":"https:\/\/ror.org\/00dr28g20","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1136\/ard-2023-224919","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T13:25:19Z","timestamp":1705497919000},"page":"464-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Pragmatic targets for moderate\/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression"],"prefix":"10.1016","volume":"83","author":[{"given":"Sofia","family":"Pitsigavdaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Nikoloudaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Garantziotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-8222","authenticated-orcid":false,"given":"Ettore","family":"Silvagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyro","family":"Repa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irini","family":"Flouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor","family":"Avgoustidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Parperis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2696-031X","authenticated-orcid":false,"given":"Antonis","family":"Fanouriakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Govoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9607-0326","authenticated-orcid":false,"given":"Prodromos","family":"Sidiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-4671","authenticated-orcid":false,"given":"Dimitrios T","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bortoluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5299-1406","authenticated-orcid":false,"given":"George","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224919_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.rdc.2019.07.001","article-title":"Treat to target in rheumatology: A historical account on occasion of the 10th anniversary","volume":"45","author":"Smolen","year":"2019","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard-2023-224919_bib2","first-page":"9","article-title":"Correction 2021Doris definition of remission in SLE: final recommendations from an international task force","volume":"9","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-224919_bib3","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large International task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224919_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/lupus-2021-000538","article-title":"DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-224919_bib5","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224919_bib6","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.40571","article-title":"Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort","volume":"70","author":"Petri","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224919_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000616","article-title":"LLDAS (lupus low disease activity state) and\/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the almenara lupus cohort","volume":"9","author":"Ugarte-Gil","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-224919_bib8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/acr.23867","article-title":"Association of achieving lupus low disease activity state fifty percent of the time with both reduced damage accrual and mortality in patients with systemic lupus erythematosus","volume":"72","author":"Sharma","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224919_bib9","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/annrheumdis-2020-217070","article-title":"Remission in systemic lupus erythematosus: testing different definitions in a large Multicentre cohort","volume":"79","author":"Saccon","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224919_bib10","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/S2665-9913(19)30048-7","article-title":"Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study","volume":"1","author":"Golder","year":"2019","journal-title":"The Lancet Rheumatology"},{"key":"10.1136\/ard-2023-224919_bib11","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Lupus low disease activity state as a treatment Endpoint for systemic lupus erythematosus: a prospective validation study","volume":"1","author":"Golder","year":"2019","journal-title":"The Lancet Rheumatology"},{"key":"10.1136\/ard-2023-224919_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/0961203320912338","article-title":"Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus","volume":"29","author":"Heijke","year":"2020","journal-title":"Lupus"},{"key":"10.1136\/ard-2023-224919_bib13","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/rheumatology\/keaa407","article-title":"Comparison of three different definitions of low disease activity in patients with systemic lupus erythematosus and their Prognostic utilities","volume":"60","author":"Kang","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224919_bib14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-022-02756-3","article-title":"\u201c\u2018not at target\u2019: prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study\u201d","volume":"24","author":"Kandane-Rathnayake","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224919_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13075-017-1256-6","article-title":"Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study","volume":"19","author":"Golder","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224919_bib16","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1093\/rheumatology\/keac185","article-title":"Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus","volume":"61","author":"Emamikia","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224919_bib17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"Update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224919_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000234","article-title":"Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? real-life data from a Monocentric cohort","volume":"5","author":"Tani","year":"2018","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-224919_bib19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/ard-2022-222748","article-title":"Lupus low disease activity state attainment in the phase 3 TULIP trials of Anifrolumab in active systemic lupus erythematosus","volume":"82","author":"Eric","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224919_bib20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/annrheumdis-2018-214427","article-title":"Lupus low disease activity state (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of Belimumab in systemic lupus erythematosus","volume":"78","author":"Oon","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224919_bib21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/annrheumdis-2018-214487","article-title":"Lupus low disease activity state (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the phase IIb MUSE trial of Anifrolumab","volume":"78","author":"Morand","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224919_bib22","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S2665-9913(19)30049-9","article-title":"Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials","volume":"1","author":"Parodis","year":"2019","journal-title":"The Lancet Rheumatology"},{"key":"10.1136\/ard-2023-224919_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13075-021-02572-1","article-title":"Disease course following high disease activity status revealed patterns in SLE","volume":"23","author":"Hoi","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224919_bib24","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the systemic lupus International collaborating clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224919_bib25","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"European League against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis & Rheumatology"},{"key":"10.1136\/ard-2023-224919_bib26","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224919_bib27","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224919_bib28","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/rheumatology\/key170","article-title":"The British society for rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224919_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015546","article-title":"Validity of the Italian algorithm for the Attribution of neuropsychiatric events in systemic lupus erythematosus: a retrospective Multicentre International diagnostic cohort study","volume":"7","author":"Bortoluzzi","year":"2017","journal-title":"BMJ Open"},{"key":"10.1136\/ard-2023-224919_bib30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the systemic lupus International collaborating clinics\/American college of rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224919_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224919_bib32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1536867X19830915","article-title":"Bootstrap Pointwise confidence intervals for Covariate-adjusted survivor functions in the Cox model","volume":"19","author":"Ruhe","year":"2019","journal-title":"The Stata Journal"},{"key":"10.1136\/ard-2023-224919_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13075-022-02869-9","article-title":"Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study","volume":"24","author":"Abe","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224919_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152226","article-title":"Factors associated with cardiovascular events in systemic lupus erythematosus in a Monocentric cohort with up to 40 years of follow-up","volume":"61","author":"Farina","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-224919_bib35","article-title":"Glucocorticoid treatment in SLE is associated with infections, comorbidities, and mortality-a national cohort study","volume":"10","author":"Frodlund","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224919_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kead148","article-title":"Clusters based on demography, disease phenotype and autoantibody status predicts mortality in lupus: data from Indian lupus cohort (INSPIRE)","author":"Kavadichanda","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224919_bib37","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/rheumatology\/ker368","article-title":"Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort","volume":"51","author":"Lopez","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224919_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.31138\/mjr.30.1.7","article-title":"Cerebrovascular events in systemic lupus erythematosus: diagnosis and management","volume":"30","author":"Nikolopoulos","year":"2019","journal-title":"Mediterr J Rheumatol"},{"key":"10.1136\/ard-2023-224919_bib39","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/1744666X.2018.1538789","article-title":"Mortality in systemic lupus erythematosus: causes, predictors and interventions","volume":"14","author":"Ocampo-Piraquive","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1136\/ard-2023-224919_bib40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3899\/jrheum.180986","article-title":"Atherosclerotic vascular events in systemic lupus erythematosus: an evolving story","volume":"47","author":"Urowitz","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224919_bib41","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1093\/rheumatology\/keac002","article-title":"Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus","volume":"61","author":"Kikuchi","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224919_bib42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/annrheumdis-2017-211613","article-title":"Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission","volume":"77","author":"Zen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224919_bib43","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus International collaborating clinics (SLICC) inception cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224919_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000066","article-title":"Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins lupus cohort","volume":"2","author":"Al Sawah","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2023-224919_bib45","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1136\/annrheumdis-2015-208669","article-title":"Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of Orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds","volume":"75","author":"Nikiphorou","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224919_bib46","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13075-020-02313-w","article-title":"Rheumatoid arthritis patients on persistent moderate disease activity on Biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group","volume":"22","author":"Genitsaridi","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224919_bib47","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1136\/annrheumdis-2013-204906","article-title":"Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes","volume":"74","author":"Ruyssen-Witrand","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224919_bib48","first-page":"967","article-title":"Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis","volume":"48","author":"Akdemir","year":"2018","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-224919_bib49","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1136\/annrheumdis-2015-207347","article-title":"Prolonged remission in Caucasian patients with SLE: prevalence and outcomes","volume":"74","author":"Zen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224919_bib50","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2665-9913(22)00304-6","article-title":"Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study","volume":"4","author":"Kandane-Rathnayake","year":"2022","journal-title":"The Lancet Rheumatology"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724000578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724000578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:18:07Z","timestamp":1739503087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724000578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0003496724000578"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224919","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pragmatic targets for moderate\/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224919","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 THE AUTHORS. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology, EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}